Metabolic Phenotyping: Breakthrough in Neuroscience
First published report of a blood-based biomarker panel with very high accuracy for detecting preclinical Alzheimer's disease (Mapstone et al., Nature Medicine, 2014). -- View Abstract -- View Press Release
Metabolomics is emerging as a powerful new technologoy platform that will play a key role in the identification of CNS biomarkers. These biomarkers can be used to identify individual at risk at the preclinical stage, provide better diagnostic and surrogate markers of disease and its progression and allow clinicians to provide a more accurate and early prognosis.
In this newsletter edition we will outline some important neurological studies (performed by Biocrates Kits), which show metabolomics’ full potential in the field of neuroscience.
Mapstone et al., Nature Medicine, 2014
Blood test predicts Alzheimer's
Discovery and validation of a set of 10 lipids from peripheral blood that predicted phenoconversion to either amnestic mild cognitive impairment or Alzheimer’s disease within a 2–3 year timeframe with over 90% accuracy.
This biomarker panel, reflecting cell membrane integrity, may be sensitive to early neuro-degeneration of preclinical Alzheimer’s disease.
Grimm et al., J Chromatogr A., 2011
Alzheimer's and Nutrition: Influence of food intake
Grimm et al., 2011, suggest that specific diet might be beneficial in Alzheimer's disease.
He et al., Transl. Psychiatry, 2012
Diagnosis of Schizophrenia
The study from He et al. illustrated that the metabolic deviations detected in plasma may serve as potential biomarkers to aid diagnosis of schizophrenia (ornithine, arginine, glutamine, histidine, PC ae C38:6).
Mandal et al., Genome Medicine, 2012
Analysis of Metabolites in CSF
The study from Mandal et al. shows that Biocrates' Metabolic Phenotyping Kits can be successfully used to perform quantitative analyses of human cerebrospinal fluid.
BIOCRATES Life Sciences AG offers unique solutions for targeted, quantitative and quality-controlled metabolic phenotyping The spectrometry-based assays are marked by unprecedented accuracy and precision, thus providing a comprehensive and predictive understanding of phenotypes and metabolic pathways.
BIOCRATES Life Sciences AG Eduard-Bodem-Gasse 8, 6020 Innsbruck